In a female patient with a platelet count of 397 ×10⁹/L and an ALT of 57 U/L, how do I calculate and interpret the Fibrosis‑4 (FIB‑4) index, and what additional information (age, AST) is needed?

Calculating and Interpreting FIB-4 in a Female Patient with Platelet Count 397 and ALT 57

What You Need to Calculate FIB-4

You cannot calculate FIB-4 with only platelets and ALT—you must obtain the patient's age and AST level. 1 The FIB-4 formula requires exactly four values: age (years) × AST (IU/L) / [platelet count (×10⁹/L) × √ALT (IU/L)]. 1, 2

The FIB-4 Formula

Once you have all four values, apply this calculation: 1, 3

FIB-4 = [Age × AST] / [Platelet count × √ALT]

For your patient:

• Age: [NEEDED]
• AST: [NEEDED]
• Platelet count: 397 ×10⁹/L
• ALT: 57 U/L

Interpreting the Result Once Calculated

Low-Risk Zone: FIB-4 <1.3 (or <2.0 if age ≥65 years)

• This threshold excludes advanced fibrosis with >90% negative predictive value. 1, 2
• Management: Reassess with repeat FIB-4 in 2–3 years while implementing lifestyle modifications (7–10% weight loss, 150–300 minutes weekly moderate-intensity exercise). 1, 2
• No hepatology referral is needed unless the score rises on repeat testing or clinical decompensation develops. 2
• Use the higher cutoff (<2.0) for patients ≥65 years to avoid overestimating fibrosis risk. 2

Indeterminate Zone: FIB-4 1.3–2.67

• This range captures 30–51% of patients in real-world practice and cannot reliably exclude or confirm advanced fibrosis. 1, 2
• Management: Obtain second-tier testing with vibration-controlled transient elastography (VCTE/FibroScan) or Enhanced Liver Fibrosis (ELF) test before making referral decisions. 1, 2
• VCTE interpretation: <8.0 kPa excludes advanced fibrosis; ≥12.0 kPa indicates high probability and mandates hepatology referral. 2
• ELF interpretation: <7.7 indicates low risk; ≥9.8 indicates high risk requiring hepatology referral. 2
• The sequential FIB-4-then-elastography approach reduces futile referrals by 81% while increasing detection of advanced fibrosis 5-fold. 2

High-Risk Zone: FIB-4 >2.67 (or >3.25 for hepatitis C)

• This threshold indicates 60–80% positive predictive value for advanced fibrosis with 97% specificity. 1, 2
• Management: Immediate hepatology referral for comprehensive evaluation, including consideration of liver biopsy or magnetic resonance elastography, hepatocellular carcinoma surveillance, and variceal screening. 1, 2
• For chronic hepatitis C specifically, use the higher cutoff of >3.25, which provides 85–90% specificity. 1, 3

Diagnostic Performance Across Populations

The FIB-4 index demonstrates an AUROC of 0.77–0.86 for detecting advanced fibrosis, with performance varying by etiology. 1 In chronic hepatitis C, FIB-4 achieves an AUROC of 0.84 for cirrhosis, outperforming APRI. 4, 2 For hepatitis B, sensitivity is approximately 69% with specificity of 71%. 4, 2 The test performs best at ruling out advanced fibrosis (high negative predictive value) rather than confirming it. 1, 2

Critical Caveats

• Age effects: FIB-4 has reduced accuracy in patients <35 years due to age-dependent calculations. 1, 2
• Disease-specific limitations: FIB-4 has lower accuracy in alcoholic liver disease and autoimmune hepatitis compared to viral hepatitis and NAFLD. 2
• Platelet considerations: Your patient's platelet count of 397 is normal, which will lower the FIB-4 score (platelets are in the denominator). 3
• ALT elevation: The ALT of 57 U/L is mildly elevated (normal <40 U/L for women), suggesting some degree of hepatocellular injury that warrants investigation. 2

Prognostic Implications

Beyond diagnosis, elevated FIB-4 scores predict future liver-related complications including hepatocellular carcinoma, liver decompensation, transplantation, and death. 2, 5 In primary care cohorts, high-risk FIB-4 scores (>2.67) are associated with a 6.64-fold increased hazard of severe liver outcomes, even in patients without known chronic liver disease. 5 Serial FIB-4 measurements can track fibrosis progression: an increase in FIB-4 of ≥0.4 per year predicts advancement to cirrhosis with an AUROC of 0.910. 6

Next Steps for Your Patient

1. Obtain the missing values: Order AST and document the patient's age to complete the calculation. 1
2. Calculate FIB-4 using the formula above. 1, 3
3. Apply the three-zone interpretation framework to determine whether the patient needs reassurance with repeat testing in 2–3 years, second-tier elastography/ELF testing, or immediate hepatology referral. 1, 2
4. Investigate the cause of the mildly elevated ALT (viral hepatitis serologies, metabolic syndrome screening, alcohol history, autoimmune markers) regardless of FIB-4 result. 2